New horizons in mesothelioma treatment/cure
The dawn of the 19th century brought along a new darling for the construction industry. Virtually every company seemed to fall in love with asbestos for its insulating property, fire resistance, and relative cost-effectiveness. Little did they know that they were weaponizing a major health threat. The devastation inhaled asbestos has produced is almost unquantifiable. Mesothelioma and asbestosis; its main offensive weapons. These are very aggressive forms of cancer and over the years. There seemed to be nothing the medical profession could do about them.
The compensations haven’t been enough to ease the near hopelessness that comes with a mesothelioma diagnosis. While it is unknown if a cure would ever be found, or when it would be found, scientists are working assiduously to ensure succor is brought to the bereaved. Here are some new hopes in Mesothelioma treatment.
Targeting immune cells have helped recorded major breakthroughs in the prognosis of many cancers. Mesothelioma appears to be joining the list soon with results from Phase 2 clinical trials showing a lot of promise. Nivolumab alone and a combination of Nivolumab and Ipilimumab have been used as immune checkpoint inhibitors and both have shown good promise although it remains to be seen which of the interventions is the superior one. The trials were carried out on patients who had been previously treated with chemotherapy but have relapsed.
Currently under research at the University of Bradford, this drug has great potential for the treatment of mesothelioma. The drug works by blocking the mechanism developed by the malignant cells in order to evade apoptosis. Apoptosis is the programmed cell death that ensures mutant cells that could turn out cancerous. These are destroyed before the process of cell division is complete. HRX9 specifically targets the HOX family, a group of genes responsible for hyperproliferation of cells, normally switched off in normal adult cells but active in mesothelioma cells. It is the first drug that would show activity in inducing apoptosis in mesotheliomas.
This is not exactly a treatment technique but it also offers great hope for a good prognosis. One of the factors responsible for the gloomy prognosis associated with Mesothelioma is that most patients present with symptoms at the late stage. Germline mutations have shown promise in identifying susceptible individuals and makes it possible for them to be targeted early for intervention.
This is another drug that is being tested in combination with other known antitumor agents. Cediranib is believed to block certain enzymes that are necessary for mesothelioma cell replication. It is also capable of starving the malignant cells of blood supply, depriving them essential nutrients and leading to ultimate death. Cediranib is currently being combined with Pemetrexed and Cisplatin and advanced clinical trials are currently ongoing.
Mesothelioma remains one of the most aggressive forms of cancer and it currently has no known cure. With the numerous programs ongoing in various cancer centers and novel discovering being uncovered. It is hoped that the 100% mortality associated with the cancer would soon change.